{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T07:17:23Z","timestamp":1780471043422,"version":"3.54.1"},"reference-count":29,"publisher":"Public Library of Science (PLoS)","issue":"3","license":[{"start":{"date-parts":[[2017,3,29]],"date-time":"2017-03-29T00:00:00Z","timestamp":1490745600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["31371399"],"award-info":[{"award-number":["31371399"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"DOI":"10.1371\/journal.pone.0174648","type":"journal-article","created":{"date-parts":[[2017,3,29]],"date-time":"2017-03-29T18:04:09Z","timestamp":1490810649000},"page":"e0174648","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":13,"title":["Rituximab maintenance therapy for patients with diffuse large B-cell lymphoma: A meta-analysis"],"prefix":"10.1371","volume":"12","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4503-0732","authenticated-orcid":true,"given":"Xuan","family":"Zhou","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tingting","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yichan","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Na","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2017,3,29]]},"reference":[{"issue":"Suppl 1","key":"ref1","first-page":"S93","article-title":"New developments in the management of diffuse large B-cell lymphoma","volume":"17","author":"TM Habermann","year":"2012","journal-title":"Hematology (Amsterdam, Netherlands)"},{"issue":"8","key":"ref2","first-page":"442","article-title":"Treatment patterns and outcomes among patients with high-intermediate\/high-risk diffuse large B-cell lymphoma in the USA","volume":"20","author":"DS Mytelka","year":"2015","journal-title":"Hematology (Amsterdam, Netherlands)"},{"issue":"22","key":"ref3","doi-asserted-by":"crossref","first-page":"5027","DOI":"10.1200\/JCO.2005.09.137","article-title":"Introduction of combined CHOP plus rituximab therapy dramatically improved outcome of diffuse large B-cell lymphoma in British Columbia","volume":"23","author":"LH Sehn","year":"2005","journal-title":"Journal of Clinical Oncology"},{"key":"ref4","first-page":"98","article-title":"Maintenance Rituximab every 2 months for 2 years is effective and well tolerated in patients with follicular lymphoma with both standard or rapid infusion: Updated results from the phase IIIb MAXIMA study","volume":"34","author":"R Foa","year":"2011","journal-title":"Onkologie"},{"issue":"9759","key":"ref5","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/S0140-6736(10)62175-7","article-title":"Rituximab maintenance for 2 years in patients with high tumour burden follicular lymphoma responding to rituximab plus chemotherapy (PRIMA): a phase 3, randomised controlled trial","volume":"377","author":"G Salles","year":"2011","journal-title":"Lancet"},{"issue":"3","key":"ref6","doi-asserted-by":"crossref","first-page":"378","DOI":"10.4103\/0366-6999.150111","article-title":"Rituximab treatment strategy for patients with diffuse large B-cell lymphoma after first-line therapy: a systematic review and meta-analysis","volume":"128","author":"YR Ren","year":"2015","journal-title":"Chinese medical journal"},{"issue":"24","key":"ref7","doi-asserted-by":"crossref","first-page":"2815","DOI":"10.1002\/(SICI)1097-0258(19981230)17:24<2815::AID-SIM110>3.0.CO;2-8","article-title":"Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints","volume":"17","author":"MKB Parmar","year":"1998","journal-title":"Statistics in Medicine"},{"issue":"19","key":"ref8","doi-asserted-by":"crossref","first-page":"3121","DOI":"10.1200\/JCO.2005.05.1003","article-title":"Rituximab-CHOP versus CHOP alone or with maintenance rituximab in older patients with diffuse large B-cell lymphoma","volume":"24","author":"TM Habermann","year":"2006","journal-title":"Journal of clinical oncology: official journal of the American Society of Clinical Oncology"},{"issue":"12","key":"ref9","doi-asserted-by":"crossref","first-page":"1985","DOI":"10.1093\/annonc\/mdp237","article-title":"Rituximab versus observation after high-dose consolidative first-line chemotherapy with autologous stem-cell transplantation in patients with poor-risk diffuse large B-cell lymphoma","volume":"20","author":"C Haioun","year":"2009","journal-title":"Annals of oncology: official journal of the European Society for Medical Oncology \/ ESMO"},{"issue":"36","key":"ref10","doi-asserted-by":"crossref","first-page":"4462","DOI":"10.1200\/JCO.2012.41.9416","article-title":"Rituximab Maintenance Therapy After Autologous Stem-Cell Transplantation in Patients With Relapsed CD20(+) Diffuse Large B-Cell Lymphoma: Final Analysis of the Collaborative Trial in Relapsed Aggressive Lymphoma","volume":"30","author":"C Gisselbrecht","year":"2012","journal-title":"Journal of Clinical Oncology"},{"issue":"5","key":"ref11","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1111\/bjh.13652","article-title":"Rituximab maintenance improves survival in male patients with diffuse large B-cell lymphoma. Results of the HD2002 prospective multicentre randomized phase III trial","volume":"171","author":"M Witzens-Harig","year":"2015","journal-title":"Br J Haematol"},{"issue":"7","key":"ref12","doi-asserted-by":"crossref","first-page":"955","DOI":"10.3324\/haematol.2015.125344","article-title":"Rituximab maintenance for patients with aggressive B-cell lymphoma in first remission: results of the randomized NHL13 trial","volume":"100","author":"U Jaeger","year":"2015","journal-title":"Haematologica"},{"issue":"21","key":"ref13","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V124.21.146.146","article-title":"Rituximab Maintenance Versus Wait and Watch after Four Courses of R-DHAP Followed By Autologous Stem Cell transplantation in Previously Untreated Young Patients with Mantle Cell Lymphoma: First Interim Analysis of the Phase III Prospective Lyma Trial, a Lysa Study","volume":"124","author":"S Le Gouill","year":"2014","journal-title":"Blood"},{"key":"ref14","first-page":"37","article-title":"Rituximab in the treatment of B-cell non-Hodgkin lymphoma, focus on outcomes and comparative effectiveness","volume":"2","author":"F Badin","year":"2010","journal-title":"ClinicoEconomics and outcomes research: CEOR"},{"issue":"2","key":"ref15","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/j.ctrv.2006.10.005","article-title":"Rituximab in lymphoma: A systematic review and consensus practice guideline from Cancer Care Ontario","volume":"33","author":"MC Cheung","year":"2007","journal-title":"Cancer Treatment Reviews"},{"issue":"1","key":"ref16","doi-asserted-by":"crossref","first-page":"44","DOI":"10.3816\/CLML.2010.n.004","article-title":"Brief-Duration Rituximab\/Chemotherapy Followed by Maintenance Rituximab in Patients With Diffuse Large B-Cell Lymphoma Who Are Poor Candidates for R-CHOP Chemotherapy: A Phase II Trial of the Sarah Cannon Oncology Research Consortium","volume":"10","author":"JD Hainsworth","year":"2010","journal-title":"Clinical Lymphoma Myeloma & Leukemia"},{"issue":"7","key":"ref17","first-page":"456","article-title":"Evaluation of the impact of maintenance rituximab in elderly patients with diffuse large B-cell lymphoma","volume":"7","year":"2007","journal-title":"Clinical Lymphoma & Myeloma"},{"issue":"1","key":"ref18","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1007\/s00432-011-1074-1","article-title":"How to determine post-RCHOP therapy for risk-tailored adult patients with diffuse large B-cell lymphoma, addition of maintenance rituximab or observation: multicenter experience","volume":"138","author":"BT Huang","year":"2012","journal-title":"Journal of Cancer Research and Clinical Oncology"},{"issue":"9","key":"ref19","first-page":"756","article-title":"Efficacy of additional two cycles of rituximab administration for patients with diffuse large B-cell lymphoma in first remission","volume":"37","author":"HJ Zhong","year":"2016","journal-title":"Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi"},{"issue":"11","key":"ref20","doi-asserted-by":"crossref","first-page":"1451","DOI":"10.1007\/s00277-013-1811-4","article-title":"Follow-up of patients receiving rituximab for diffuse large B cell lymphoma: an overview of systematic reviews","volume":"92","author":"LP Lindenmeyer","year":"2013","journal-title":"Ann Hematol"},{"issue":"6","key":"ref21","doi-asserted-by":"crossref","first-page":"E111","DOI":"10.1002\/ajh.23996","article-title":"Updated survival analysis of two sequential prospective trials of R-MACLO-IVAM followed by maintenance for newly diagnosed mantle cell lymphoma","volume":"90","author":"PJ Hosein","year":"2015","journal-title":"American journal of hematology"},{"issue":"11","key":"ref22","doi-asserted-by":"crossref","first-page":"1393","DOI":"10.1038\/bmt.2015.184","article-title":"Post-autologous transplant maintenance therapies in lymphoid malignancies: are we there yet?","volume":"50","author":"N Epperla","year":"2015","journal-title":"Bone marrow transplantation"},{"issue":"11","key":"ref23","doi-asserted-by":"crossref","first-page":"e480","DOI":"10.3324\/haematol.2015.133223","article-title":"Comment on &quot;Rituximab maintenance for patients with aggressive B-cell lymphoma in first remission: results of the randomized NHL13 trial&quot;","volume":"100","author":"TP Vassilakopoulos","year":"2015","journal-title":"Haematologica"},{"issue":"6","key":"ref24","doi-asserted-by":"crossref","first-page":"924","DOI":"10.3109\/0284186X.2015.1026455","article-title":"Male gender is an adverse risk factor only in young patients with diffuse large B-cell lymphoma\u2014a Swedish population-based study","volume":"54","author":"G Hedstrom","year":"2015","journal-title":"Acta Oncologica"},{"issue":"2","key":"ref25","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1111\/j.1600-0609.2010.01541.x","article-title":"Male gender is an adverse prognostic factor in B-cell lymphoma patients treated with immunochemotherapy","volume":"86","author":"S Riihijarvi","year":"2011","journal-title":"European Journal of Haematology"},{"issue":"5","key":"ref26","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1182\/blood-2013-07-517037","article-title":"Suboptimal dosing of rituximab in male and female patients with DLBCL","volume":"123","author":"M Pfreundschuh","year":"2014","journal-title":"Blood"},{"issue":"14","key":"ref27","doi-asserted-by":"crossref","first-page":"3276","DOI":"10.1182\/blood-2011-09-380949","article-title":"The role of sex and weight on rituximab clearance and serum elimination half-life in elderly patients with DLBCL","volume":"119","author":"C Muller","year":"2012","journal-title":"Blood"},{"issue":"11","key":"ref28","doi-asserted-by":"crossref","first-page":"1747","DOI":"10.1007\/s00277-012-1516-0","article-title":"Prognostic relevance of pretreatment quality of life in diffuse large B-cell lymphoma patients treated with rituximab-CHOP: Results from a prospective cohort study","volume":"91","author":"HA Jung","year":"2012","journal-title":"Annals of Hematology"},{"issue":"7","key":"ref29","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.3109\/10428194.2011.566951","article-title":"Quality of life in 269 patients with poor-risk diffuse large B-cell lymphoma treated with rituximab versus observation after autologous stem cell transplant","volume":"52","author":"N Heutte","year":"2011","journal-title":"Leuk Lymphoma"}],"container-title":["PLOS ONE"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/dx.plos.org\/10.1371\/journal.pone.0174648","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,10,4]],"date-time":"2020-10-04T16:14:17Z","timestamp":1601828057000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0174648"}},"subtitle":[],"editor":[{"given":"Joseph S","family":"Pagano","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2017,3,29]]},"references-count":29,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2017,3,29]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0174648","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,3,29]]}}}